CD19已成为滤泡性淋巴瘤的重要且新颖的治疗靶点。 CD19靶向疗法，包括单克隆抗体、双特异性抗体和CAR T细胞疗法，为治疗滤泡性淋巴瘤和改善预后提供了有前景的途径。我们回顾了靶向CD19在滤泡性淋巴瘤中的作用和原理，以及CD19靶向的不同干预措施，例如如细胞疗法、双特异性抗体、抗体-药物缀合物和单克隆抗体。最后我们讨论了这些疗法如何影响滤泡性淋巴瘤的治疗前景。CD19 是滤泡性淋巴瘤治疗开发的一个有吸引力的靶标。鉴于其有效性，它将作为一种有前途的治疗这种疾病的方法继续向前发展。

CD19 has emerged as an important and novel therapeutic target in follicular lymphoma. CD19-directed therapies, including monoclonal antibodies, bispecific antibodies, and CAR T-cell therapies, offer promising avenues for treating follicular lymphoma and improving outcomes.We review the role and rationale of targeting CD19 in follicular lymphoma and different interventions of CD19 targeting, such as cell therapy, bispecific antibodies, antibody-drug conjugates, and monoclonal antibodies. We finalize with a discussion on how these therapies may influence the treatment landscape of follicular lymphoma.CD19 is an attractive target for therapeutic development in follicular lymphoma. Given its effectiveness, it will continue to move forward as a promising therapy for this disease.